Characterization of TGFB-Dependent Mechanoresponses by Aortic Smooth Muscle Cells
主动脉平滑肌细胞 TGFB 依赖性机械反应的表征
基本信息
- 批准号:9380043
- 负责人:
- 金额:$ 59.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-19 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAngiotensin II ReceptorAnimalsAortaApoptosisArchitectureAtrophicBiomechanicsBlood PressureCell physiologyCellsClinicalClinical TrialsCollagen FiberCollectionContinuous InfusionContractile ProteinsDNA Sequence AlterationDevelopmentDilatation - actionDiseaseDisease ProgressionDissectionElastic FiberElastinExtracellular MatrixFBN1FailureFemaleGenetic TranscriptionGlycoproteinsGoalsHomeostasisHumanHyperplasiaHypertensionHypertrophyIn VitroInstructionIntegrinsInvestigationLeadLigandsLinkLosartanMarfan SyndromeMechanical StressMechanicsMedicalMedical GeneticsMedical ImagingMicrofibrilsModelingMolecularMolecular TargetMorbidity - disease rateMorphologyMusPathologyPeptide HydrolasesPharmacotherapyPhysiologicalPlayProcessProductionProteolysisRisk FactorsRoleRuptureSerologicalSignal TransductionSmooth MuscleSmooth Muscle MyocytesSpecimenStressStress FibersStructureSyndromeTGFB1 geneTGFBR1 geneTGFBR2 geneTestingTherapeuticThoracic Aortic AneurysmThoracic aortaTimeTissuesTransforming Growth Factor betaVasoconstrictor AgentsWorkascending aortaexperiencegene producthemodynamicsimprovedin vivoin vivo Modelmalemechanical forcemechanical loadmechanotransductionmortalitymouse modelnovelpostnatalpressurepublic health relevancereceptorresponsetargeted treatment
项目摘要
PROJECT SUMMARY
Thoracic aortic aneurysms (TAAs) affect young and old males and females and are responsible for significant
morbidity and mortality. Findings over recent years suggest that an aberrant activity of or signaling through
transforming growth factor-beta (TGFβ) plays important roles in TAAs, yet controversy remains regarding the
precise mechanisms. This lack of understanding continues to hinder the identification of improved therapeutic
approaches as revealed by the recent failure of a highly anticipated clinical trial of losartan, an angiotensin-II
receptor antagonist. We and others recently hypothesized that the collection of predisposing genetic mutations
suggests that TAAs result from a compromised cellular mechanosensing and mechanoregulation of the
extracellular matrix that endows the aortic wall with its structural integrity. Importantly, TGFβ can be viewed, in
part, as an important mechanotransducer – its production and activation are mechanosensitive and its
downstream gene products include the contractile proteins that are fundamental to sensing and
regulating the extracellular matrix that is produced in response to its increased signaling.
The goal of our work is to test novel hypotheses on interactions among the structural and instructional roles of
altered TGFβ signaling, smooth muscle cell mechanosensing of altered wall stresses (particularly those due to
hypertension, a primary risk factor for TAAs), and the integrity of fibrillin-1, an essential glycoprotein that
associates with elastin to form elastic fibers. Towards this end, we will use a combination of new genetically
modified mouse models, in vivo models of induced hypertension, and clinical specimens of TAAs. Specifically,
we will characterize responses of smooth muscle cells in the thoracic aorta to increased wall stresses and
disrupted fibrillin-1 that depend on TGFβ signaling and lead to maladaptive remodeling of the aortic wall. The
results of our work will thereby provide the first mechanistic investigation of roles of TGFβ signaling in cases of
hypertension (a major risk factor for TAAs) and compromised extracellular matrix (fibrillin-1, the cause of the
majority of syndromic TAAs) while testing, for the first time, the recently proposed hypothesis that dysfunctional
smooth muscle mechanosensing and mechanoregulation of matrix underlies many different causes of TAAs. In
particular, we suggest that smooth muscle cells will invoke an atrophic process if they sense stresses lower than
homeostatic even in cases wherein the actual stress is normal or higher than normal, which will drive the wall
toward aneurysmal development. The characterization of TGFβ-dependent mechanoresponses by aortic smooth
muscle cells may identify new molecular targets to treat TAAs, a lethal disease and without current
pharmacotherapy.
项目摘要
胸主动脉瘤(TAAs)影响年轻和老年男性和女性,并导致显著的
发病率和死亡率。近年来的研究结果表明,一个异常的活动或信号通过
转化生长因子-β(TGFβ)在TAAs中起重要作用,但关于其在TAAs中的作用仍存在争议。
精确的机制。这种缺乏了解继续阻碍着确定改进的治疗方法。
最近一项备受期待的氯沙坦(一种血管紧张素II)临床试验失败,
受体拮抗剂我们和其他人最近假设,
表明TAAs是由受损的细胞机械感受和机械调节引起的。
赋予主动脉壁结构完整性的细胞外基质。重要的是,TGFβ可以在
部分,作为一个重要的机械传感器-其生产和激活是机械敏感的,
下游基因产物包括对传感至关重要的收缩蛋白,
调节响应其增加的信号传导而产生的细胞外基质。
我们工作的目标是测试新的假设之间的相互作用的结构和教学的作用,
改变的TGFβ信号传导,平滑肌细胞对改变的壁应力的机械感受(特别是那些由于
高血压,TAAs的主要危险因素),以及HLA-I的完整性,HLA-I是一种必需的糖蛋白,
与弹性蛋白结合形成弹性纤维。为此,我们将使用一种新的基因组合,
改良的小鼠模型、诱导性高血压的体内模型和TAA的临床标本。具体地说,
我们将描述胸主动脉中平滑肌细胞对增加的壁应力的反应,
破坏依赖于TGFβ信号传导并导致主动脉壁适应不良重塑的β-淀粉样蛋白-1。的
因此,我们的工作结果将为TGFβ信号转导在以下情况下的作用提供第一个机制研究:
高血压(TAAs的主要危险因素)和受损的细胞外基质(细胞外基质蛋白-1,TAAs的原因),
大多数综合征TAAs),同时首次测试最近提出的假设,即功能障碍
平滑肌机械感应和基质的机械调节是TAA的许多不同原因的基础。在
特别是,我们认为,平滑肌细胞将调用一个萎缩的过程,如果他们感觉应力低于
即使在实际应力正常或高于正常的情况下,也能保持体内平衡,从而驱动墙壁
发展缓慢。主动脉平滑肌细胞TGFβ依赖性机械反应的特征
肌肉细胞可以识别新的分子靶点来治疗TAA,这是一种致命的疾病,
药物治疗.
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jay D. Humphrey其他文献
A Computational Framework to Predict and Understand in situ Heart Valve Tissue Engineering
- DOI:
10.1080/24748706.2021.1900703 - 发表时间:
2021-06-01 - 期刊:
- 影响因子:
- 作者:
Elmer Middendorp;Marcos Latorre;Jason M. Szafron;Frank P.T. Baaijens;Jay D. Humphrey;Sandra Loerakker - 通讯作者:
Sandra Loerakker
ブレインサイエンス・レビュー2004
脑科学评论 2004
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:0
- 作者:
Daisuke Mori;Guido David;Jay D. Humphrey;James E. Moore Jr.;Miho Terunuma;平田 雅人 - 通讯作者:
平田 雅人
Multi-Scale Multi-Cell Computational Model of Inflammation-Mediated Aortic Remodeling in Hypertension
- DOI:
10.1007/s10439-025-03685-3 - 发表时间:
2025-02-04 - 期刊:
- 影响因子:5.400
- 作者:
Ana C. Estrada;Jay D. Humphrey - 通讯作者:
Jay D. Humphrey
Journal of Mechanics of Materials and Structures SPONTANEOUS UNWINDING OF A LABILE DOMAIN IN A COLLAGEN TRIPLE HELIX
材料与结构力学杂志 胶原三螺旋中不稳定域的自发展开
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Krishnakumar M. Ravikumar;Jay D. Humphrey;Wonmuk Hwang - 通讯作者:
Wonmuk Hwang
Altered mechanical behavior and properties of the human anterior lens capsule after cataract surgery.
白内障手术后人类晶状体前囊的机械行为和特性发生改变。
- DOI:
10.1016/j.exer.2009.06.001 - 发表时间:
2009 - 期刊:
- 影响因子:3.4
- 作者:
R. Pedrigi;J. Dziezyc;Jay D. Humphrey - 通讯作者:
Jay D. Humphrey
Jay D. Humphrey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jay D. Humphrey', 18)}}的其他基金
Computational model-driven design to mitigate vein graft failure after coronary artery bypass
计算模型驱动的设计可减轻冠状动脉搭桥术后静脉移植失败的风险
- 批准号:
10683327 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
Computational model-driven design to mitigate vein graft failure after coronary artery bypass
计算模型驱动设计减轻冠状动脉搭桥术后静脉移植失败
- 批准号:
10539814 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
Modeling Multiscale Immuno-Mechanics in Aortic Disease
主动脉疾病的多尺度免疫力学建模
- 批准号:
10532786 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
Modeling Multiscale Immuno-Mechanics in Aortic Disease
主动脉疾病的多尺度免疫力学建模
- 批准号:
10352581 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection
胸主动脉瘤和夹层中的平滑肌细胞增殖和降解表型
- 批准号:
10184861 - 财政年份:2020
- 资助金额:
$ 59.94万 - 项目类别:
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection
胸主动脉瘤和夹层中的平滑肌细胞增殖和降解表型
- 批准号:
10376852 - 财政年份:2019
- 资助金额:
$ 59.94万 - 项目类别:
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection
胸主动脉瘤和夹层中的平滑肌细胞增殖和降解表型
- 批准号:
10573756 - 财政年份:2019
- 资助金额:
$ 59.94万 - 项目类别:
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection
胸主动脉瘤和夹层中的平滑肌细胞增殖和降解表型
- 批准号:
10132382 - 财政年份:2019
- 资助金额:
$ 59.94万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 59.94万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 59.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 59.94万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 59.94万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 59.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 59.94万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 59.94万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 59.94万 - 项目类别:














{{item.name}}会员




